Sarepta Therapeutics (NASDAQ:SRPT) Earns "Equal Weight" Rating from Morgan Stanley

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "equal weight" rating reissued by equities research analysts at Morgan Stanley in a research note issued to investors on Monday, Marketbeat.com reports.

Several other research analysts have also weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 20th. Evercore ISI cut Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 target price for the company. in a research note on Thursday, May 8th. Needham & Company LLC lowered their price target on shares of Sarepta Therapeutics from $125.00 to $50.00 and set a "buy" rating for the company in a report on Monday. Royal Bank of Canada dropped their price objective on Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating on the stock in a research note on Wednesday, May 7th. Finally, BMO Capital Markets downgraded Sarepta Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $120.00 to $70.00 in a research note on Monday. One analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $99.35.

Sarepta Therapeutics Price Performance

NASDAQ SRPT traded down $15.25 on Monday, hitting $20.93. 41,637,119 shares of the company were exchanged, compared to its average volume of 1,973,820. Sarepta Therapeutics has a 1-year low of $18.33 and a 1-year high of $173.25. The firm has a 50 day moving average of $46.25 and a two-hundred day moving average of $86.03. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market cap of $2.06 billion, a P/E ratio of 16.74 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. During the same period in the previous year, the business earned $0.73 EPS. The firm's revenue was up 80.2% compared to the same quarter last year. On average, equities analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. EP Wealth Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 2.2% in the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock worth $606,000 after buying an additional 105 shares during the last quarter. Manchester Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Sarepta Therapeutics by 5.1% during the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after purchasing an additional 139 shares during the period. PNC Financial Services Group Inc. increased its holdings in Sarepta Therapeutics by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock worth $352,000 after buying an additional 145 shares during the period. Finally, Virtus ETF Advisers LLC raised its position in Sarepta Therapeutics by 6.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company's stock worth $342,000 after buying an additional 174 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.